Mina Nikanjam

Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations

Nectin-4 expression patterns and therapeutics in oncology

Tumour-agnostic kinase inhibitors

Novel clinical trial designs emerging from the molecular reclassification of cancer

Viewing the immune checkpoint VISTA: landscape and outcomes across cancers

At the right dose: personalised (N-of-1) dosing for precision oncology

Fexofenadine Plasma Concentrations to Estimate Systemic Exposure in Healthy Adults Using a Limited Sampling Strategy with a Population Pharmacokinetic Approach

Liquid biopsy: current technology and clinical applications

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Review of precision cancer medicine: Evolution of the treatment paradigm

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds

Targeting fusions for improved outcomes in oncology treatment

Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults

ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways

Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience